Summary
Vertex Pharmaceuticals reported robust financial performance for the quarter and six months ended June 30, 2020, driven by a significant surge in product revenues. Total revenues increased by 62% and 69% year-over-year for the respective periods, primarily fueled by the strong launch and uptake of TRIKAFTA. This impressive revenue growth translated into a substantial increase in net income, which more than tripled year-over-year for both the quarter and the six-month period. Despite increased operating expenses, particularly in research and development and sales, general, and administrative functions to support pipeline expansion and commercialization efforts, Vertex maintained strong operational profitability. The company's balance sheet remains strong, with a significant increase in cash, cash equivalents, and marketable securities, providing ample liquidity. Vertex continues to advance its diverse pipeline beyond cystic fibrosis, with promising developments in areas like sickle cell disease, beta-thalassemia, alpha-1 antitrypsin deficiency, and APOL1-mediated kidney diseases. The company is also actively managing its capital structure, including ongoing share repurchase programs and a revolving credit facility, to support its strategic objectives and long-term growth.
Financial Highlights
51 data points| Revenue | $1.52B |
| Cost of Revenue | $184.52M |
| Gross Profit | $1.34B |
| R&D Expenses | $420.93M |
| SG&A Expenses | $191.80M |
| Operating Expenses | $806.45M |
| Operating Income | $718.03M |
| Interest Expense | $13.87M |
| Net Income | $837.27M |
| EPS (Basic) | $3.22 |
| EPS (Diluted) | $3.18 |
| Shares Outstanding (Basic) | 259.64M |
| Shares Outstanding (Diluted) | 263.40M |
Key Highlights
- 1Total revenues grew substantially, up 62% for the quarter and 69% for the six months ended June 30, 2020, compared to the prior year.
- 2Product revenues saw a significant increase of 62% and 69% for the quarter and six months, respectively, largely driven by the strong performance of TRIKAFTA.
- 3Net income more than tripled year-over-year for both the quarter ($837.3M vs $267.4M) and the six-month period ($1.44B vs $536.1M).
- 4Diluted Earnings Per Share (EPS) also saw a significant increase, rising to $3.18 for the quarter and $5.46 for the six months, up from $1.03 and $2.06, respectively.
- 5Research and Development (R&D) expenses increased by 11% and 21% for the quarter and six months, respectively, reflecting continued investment in pipeline expansion.
- 6The company's liquidity position is strong, with cash, cash equivalents, and marketable securities totaling $5.5 billion as of June 30, 2020, an increase of $1.6 billion from the end of 2019.